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The analysis of global and comparative genomics between different diseases allows
us to understand the key biological processes that explain the etiology of these
pathologies. We have used this type of approach to evaluate the expression of several
neurodegeneration-related genes on the development of tumors, particularly brain
tumors of glial origin (gliomas), which are an aggressive and incurable type of cancer. We
have observed that genes involved in Amyotrophic lateral sclerosis (ALS), as well as in
Alzheimer’s and Parkinson’s diseases, correlate with better prognosis of gliomas. Within
these genes, high Tau/MAPT expression shows the strongest correlation with several
indicators of prolonged survival on glioma patients. Tau protein regulates microtubule
stability and dynamics in neurons, although there have been reports of its expression in
glial cells and also in gliomas. However, little is known about the regulation of Tau/MAPT
transcription in tumors. Moreover, our in silico analysis indicates that this gene is also
expressed in a variety of tumors, showing a general correlation with survival, although its
function in cancer has not yet been addressed. Another remarkable aspect of Tau is its
involvement in resistance to taxanes in various tumors types such as breast, ovarian and
gastric carcinomas. This is due to the fact that taxanes have the same tubulin-binding
site as Tau. In the present work we review the main knowledge about Tau function and
expression in tumors, with a special focus on brain cancer. We will also speculate with
the therapeutic implications of these findings.
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INTRODUCTION
Although the incidence of cancer and neurodegenerative diseases increases with age, there are
plenty of evidences of an inverse comorbidity of these two conditions. The inverse association
with cancer has been observed for Parkinson’s disease (PD) (Moller et al., 1995; Inzelberg and
Jankovic, 2007), as well as for Hungtington’s disease (HD) (Sorensen et al., 1999). Moreover, a
decreased risk of tumor incidence has been found after the onset of amyotrophic lateral sclerosis
(ALS) (Gibson et al., 2016), although having a cancer diagnosis was not associated with an overall
risk of ALS (Fang et al., 2013; Freedman et al., 2014). In the case of Alzheimer’s disease (AD), the
inverse comorbidity seems to be maintained in both directions, that is, older people with a history
of cancer have a reduced risk of AD, and individuals diagnosed with AD have a decreased risk to
develop tumors (Roe et al., 2005, 2010; Driver et al., 2012; Musicco et al., 2013; Ou et al., 2013;
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Catala-Lopez et al., 2014; Ma et al., 2014). The inverse association
between neurodegenerative and oncological diseases appears
across many individual types of cancer, even though some studies
have reported a positive association of PD with melanoma
and prostate cancer (Liu et al., 2011; Kareus et al., 2012).
For AD patients there is a more significant decreased risk of
lung cancer (Musicco et al., 2013; Ou et al., 2013), and the
“protective effect” of previous tumors seems to be greater for
smoking related cancers (Driver et al., 2012). Nevertheless, the
relationship between smoking and AD is still conflicted. Other
question that remains unanswered is what happen with less
frequent cancers, like for example brain malignancies, which
occur in the same tissue and with the same range of age of
the neurodegenerative diseases. The epidemiological evidences
in this type of tumors are scarce and sometimes contradictory
as they even suggest a direct co-occurrence with AD (Driver
et al., 2012). Moreover, a positive correlation has been found
between the mortality rate of AD and malignant brain cancer
in US (Lehrer, 2010, 2018). Anyhow, these findings support
the idea that the two diseases share some environmental
and/or genetic risks or that they are governed by similar
biological pathways.
Here, we have performed a comprehensive meta-analysis
of the genomic and transcriptomic status of genes related
to neurodegenerative diseases in brain cancer, particularly
in tumors of glial origin (gliomas). Gliomas constitute
the most common primary brain tumors and they include
astrocytomas, which resemble astrocytes at the histological level,
and oligodendrogliomas, with similarities with oligodendrocytes.
They are all characterized by their diffuse nature although
the WHO (World Health Organization) classify them from
the less aggressive grade II, to the grade IV glioblastomas
(GBM), whose median overall survival is approximately
15 months (Ceccarelli et al., 2016). Our in silico data show a
striking inverse correlation between the expression of some
of the neurodegenerative genes, especially Tau/MAPT, and
the clinical progression of gliomas. Here we discuss what
could be the implications of these observations and we extend
it to the analysis of Tau/MAPT in other cancers, where
this gene has been associated with resistance to taxanes.
The comparative analysis of the biological processes that
orchestrate the appearance and the development of gliomas
and those that participate in neurodegenerative diseases
may potentially lead to a better understanding of both
conditions and therefore to the development of more effective
therapeutic interventions.
MATERIALS AND METHODS
Analysis of Somatic Mutations and Copy
Number Variations
Genetic alterations were analyzed using the TCGA (The Cancer
Genome Atlas) data sets. For AD, the genes included were APP,
Tau/MAPT, PSEN1, PSEN2; APOE, and GSK3B; for PD, the
genes were GBA, LRRK2, PARK2 (PRKN), PARK7, PINK1, SNCA,
and UCHL1; for ALS, the genes were C9orf72, TARDBP, SOD1,
FUS, UBQLN2, and HNRNPA2B1, which were downloaded from
cBioPortal1 and UCSC cancer browser TCGA databases2.
Gene Expression Analysis
Information about the progression and the histological types
of gliomas was retrieved from the TCGA dataset that includes
GBM3 and LGG (Lower Grade Gliomas)4. These parameters
were analyzed together with the expression values of APP,
Tau/MAPT, APOE, PARK2, PARK7, PINK1, SNCA, UCHL1,
UBQLN2, and HNRNPA2B15,6. The expression of Tau/MAPT in
different cancers was retrieved from the TCGA PAN-CANCER
and GTEx dataset7,8,9.
In silico Survival Analyses
The expression of Tau/MAPT and the follow-up overall
survival data from human glioma tumors corresponding to
TCGA datasets were downloaded from Xena cancer Browser
see text footnote 5 and Gliovis10, respectively. Kaplan-Meier
survival curves were done following patient stratification using
Tau/MAPT expression values. TCGA-gliomas LGG + GBM
patients (n = 690) were stratified in two groups using Tau/MAPT
median values as thresholds. The significance of the differences
in overall survival between groups were calculated using the
Log-rank test as Mantel-Cox (Chi square).
Detailed description of how TCGA samples have been
processed to generate the dataset of somatic mutations, copy
number variations and RNA-seq has been described for LGG
dataset [N. Engl. J. Med. 2015 June 25; 372(26):2481–2498] and
GBM dataset [Cell. 2013 October 10; 155(2):462–477].
Primary Glioma Cells
The primary glioma cell lines were obtained by dissociation
of surgical specimens from “Hospital 12 de Octubre” (Madrid,
Spain), after patient’s written consent and with the approval
of the Ethical Committee (CEI 14/023). They belong to the
Biobank of that Hospital. Cells were grown in complete media
(CM): Neurobasal supplemented with B27 (1:50) and GlutaMAX
(1:100) (Thermo Fisher Scientific); penicillin-streptomycin
(1:100) (Lonza); 0.4% heparin (Sigma-Aldrich); and 40 ng/ml
EGF and 20 ng/ml bFGF2 (Peprotech).
Mouse Xenograft Assays
Animal care and experimental procedures were performed in
accordance to the European Union and National guidelines
for the use of animals in research and were reviewed
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Committee at our institution (Instituto de Salud Carlos
III, Madrid) (PROEX 244/14). For heterotopic xenografts,
1 × 106 cells were resuspended in culture media with
Matrigel (1:10, BD) and then subcutaneously injected into
athymic nude Foxn1nu mice (Harlan Iberica). For orthotopic
xenografts, stereotactically guided intracranial injections in
athymic nude Foxn1nu mice were performed by administering
0.5 × 105 cells resuspended in 2 µl of Complete Media.
The injections were made into the striatum (coordinates:
A-P, –0.5 mm; M-L, +2 mm; D-V, –3 mm; related to
Bregma) using a Hamilton syringe. Mice were sacrificed at the
onset of symptoms.
Tumor Tissue Analysis
At the endpoint, subcutaneous tumors or brain tumors were
dissected and the tissue was fresh frozen for molecular
analysis or fixed o/n in 4% paraformaldehyde (Merck) and
embedded in paraffin. Paraffin embedded tissue was cut with a
microtome (Leica Microsystems) (3 µm sections) and sections
were stained with specific antibodies. For that, slides were
heated at 60◦C for 1 h followed by deparaffinization and
hydration, washed with water, placed into antigen retrieval
solution (pressure cooking) in 10 mM sodium citrate pH
6.0 for 10 min. Paraffin sections were permeabilized with
1% Triton X-100 (Sigma-Aldrich) in PBS and blocked for
1 h in PBS with 5% BSA (Sigma), 10% FBS (Sigma), and
0,1% Triton X-100 (Sigma). The following primary antibodies
(anti-Tau, Dako A0024; anti-Ki67, Dako M7240 and anti-
GFAP, M 0761) were incubated O/N at 4◦C. The second day,
section was washed with PBS three times prior to incubation
with the appropriate fluorescent secondary antibody (anti-
mouse and anti rabbit Jackson immunoresearch) for 2 h at
room temperature. Prior to coverslip application, nuclei were
counterstained with DAPI and imaging was done with Leica SP-5
confocal microscope.
Western Blot Analysis
For protein expression analysis, a piece of tissue was processed
by mechanical disruption in lysis buffer (Tris–HCl pH 7.6,
1 mM EDTA, 1 mM EGTA, 1% SDS, and 1% Triton
X100) followed by heating for 15 min at 96◦C. Protein
content was quantified using BCA Protein Assay Kit (Thermo
Fisher Scientific). Approximately 20 µg of proteins were
resolved by 10% or 12% SDS-PAGE and they were then
transferred to a nitro cellulose membrane (Hybond-ECL,
Amersham Biosciences). The membranes were blocked for
1 h at room temperature in TBS-T [10 mM Tris–HCl
(pH 7.5), 100 mM NaCl, and 0.1% Tween-20] with 5%
skimmed milk, and then incubated overnight at 4◦C with
the corresponding primary antibody (anti-Tau Calbiochem,
577801 and anti-Actin Sigma, A2228) diluted in TBS-T.
After washing 3 times with TBS-T, the membranes were
incubated for 2 h at room temperature with their corresponding
secondary antibody (HRP-conjugated anti mouse or anti
rabbit, Amersham) diluted in TBS-T. Proteins were visible
by enhanced chemiluminiscence with ECL (Pierce) using the
Amersham Imager 680.
qRT-PCR Assay
RNA was extracted from the tissue using RNA isolation
Kit (Roche). Total RNA (1 µg) was reverse transcribed with
PrimeScript RT Reagent Kit (Takara). Quantitative real-time PCR
was performed using the Light Cycler 1.5 (Roche) with the SYBR
Premix Ex Taq (Takara). The primers used for each reaction
were Tau/MAPT Fw-GTCGAAGATTGGGTCCCTGG; Rv-
GGTCGTAGGGCTGCTGGAA and HPRT Fw-TGACACTGG
CAAAACAATGCA; Rv- GGTCCTTTTCACCAGCAAGCT.
Gene expression was quantified by the delta-delta Ct method.
Statistical Analysis
Quantitative data, represented as mean ± SD, were compared
between groups using two-tailed Student’s t or multiple ANOVA
test. One-way ANOVA analysis was used to establish the
differences of gene expression data between three groups
and was represented as F value (F = the ratio of two
mean square values). Differences are presented with statistical
significance or p value (n.s., not significant). For survival study,
patients were grouped into two groups with high and low
expression of the gene of interest using median values and
were analyzed by Kaplan-Meier method and log-rank tests using
GraphPad program.
RESULTS
Genetic Status of Molecules Associated
With Neurogedegenerative Diseases in
Gliomas
To begin to address if there is a molecular correlation
between gliomas and neurodegenerative diseases we analyzed
the TCGA merge dataset for LGG and GBM (Ceccarelli
et al., 2016) looking for the presence of mutations and copy
number alterations in genes associated with AD, PD, and
ALS. The genes we chose for AD were APP (Amyloid Beta
Precursor Protein); Tau/MAPT; PSEN1 (Presenilin 1), PSEN2
(Presenilin 2), APOE (Apolipoprotein E), and GSK3B (Glycogen
Synthase Kinase 3 Beta). For PD the genes analyzed were GBA
(Glucosylceramidase Beta), LRRK2 (Leucine Rich Repeat Kinase
2), PARK2 (Parkin RBR E3 Ubiquitin Protein Ligase), PARK7
(Parkinsonism Associated Deglycase), PINK1 (PTEN Induced
Kinase 1), SNCA (Synuclein Alpha), and UCHL1 (Ubiquitin
C-Terminal Hydrolase L1). Finally, the genes analyzed for ALS
were C9orf72 (C9orf72-SMCR8 complex subunit); TARDBP
(TAR DNA Binding Protein), SOD1 (Superoxide Dismutase
1); FUS (FUS RNA Binding Protein), UBQLN2 (Ubiquilin 2)
and HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein
A2/B1). Figure 1A shows that there is a very low frequency
of somatic mutations or copy number variations (CNV) in
glioma samples for all the genes included in the study. The
higher percentage of genetic alterations was found in the C9orf7
gene (3%), mainly associated with deep deletions that, in any
case, are not frequently found in ALS patients. Overall, these
results suggest that genetic alterations in genes associated with
neurodegeneration are not common drivers of gliomas.
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FIGURE 1 | Genetic status and gene expression of neurodegeneration-related genes in cancerous and normal tissues. (A) Histogram showing non-silent somatic
mutations and copy number variations of genes commonly altered in AD, PD, and ALS on the TCGA cohort of diffuse gliomas (n = 789), grouped according to the
WHO classification (histological type). (B,C) Box plots showing Tau/MAPT relative mRNA levels in different normal tissues (B) and tumors (C), extracted from
TCGA-TARGET-GTEx cohort, with RNAseq-normalized mRNA expression data.
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Expression of Genes Related to
Neurodegenerative Diseases in Gliomas
To further assess the involvement of the selected genes in the
pathology of gliomas, we analyzed their levels of expression
on the same TCGA cohort (Ceccarelli et al., 2016). We
summarize in Table 1 the results obtained for those genes
that showed significant changes associated with the disease. It
is noteworthy that the expression of most of these candidates
appear diminished when we compare primary tumors with
normal tissue. Moreover, their levels are even lower after tumor
recurrence, suggesting that most of these neurodegeneration-
related genes are downregulated as the brain pathology
progress. By contrast, the opposite trend was observed for
the HNRNPA2B1 gene, which is highly expressed in recurrent
tumors compared to primary gliomas or in the latter vs. normal
tissue (Table 1).
Following the same type of analysis, we evaluated the
expression of the selected genes in relation to the histological
grade: from LGG (grade 2 and 3) to the aggressive grade 4 GBMs.
In agreement with the previous data, the expression of most of
the genes decrease as the tumor grade increases. In the particular
case of HNRNPA2B1, we did not find a direct correlation with the
histological grade as the expression levels were higher in grade 3
than in grade 2 or 4 tumors (Table 1).
Finally, we studied what was the implication of the expression
of these genes in the survival of glioma patients. Except for
UCHL1 and HNRNPA2B1, we found that the high transcriptional
levels of the rest of the selected genes are associated significantly
with a decrease in tumor burden (Table 1). Taken together, these
data supports the notion that the expression of many genes
associated with neurodegenerative diseases correlate inversely
with the progression of the glioma pathology. The strongest
correlation was observed for Tau/MAPT so we hypothesized that
it must play an important role in gliomas, slowing down or
preventing the clinical evolution of these tumors. It is worth
mentioning that even though the Tau protein is mostly found
in neurons, there are few reports of its expression in glial cells
and also in brain tumors of glial origin (Miyazono et al., 1993;
LoPresti et al., 1995), reinforcing the need for a deep analysis
of the function of this protein in gliomas. Besides, we could get
some insights on the oncogenic role of Tau by addressing its
significance in other cancers.
Expression of Tau/MAPT in Cancer
The primary function of Tau protein is the regulation of the
dynamic instability of neuronal microtubules during synaptic
transmission (Avila et al., 2016; Wang and Mandelkow, 2016).
Moreover, tubulin and microtubules are the key components
of the mitotic spindle and therefore they control the cell cycle.
Actually, microtubule destabilizing and stabilizing components,
which include taxanes, have been widely used as anticancer
agents as they induce cell cycle arrest and apoptosis (Loong and
Yeo, 2014). Because Tau compete with taxanes for the same
tubulin-binding domain, a higher expression of this protein
has been linked to resistance to these type of compounds,
mainly in non-neuronal cancers (Kar et al., 2003). These
observations are related to the fact that Tau expression could
be expressed in other tissues outside the brain, as it has been
already described (Caillet-Boudin et al., 2015). To corroborate
these affirmations, we performed an in silico analysis of the
levels of Tau/MAPT mRNA in normal and cancerous tissues
in different organs. As expected, the highest expression of
this gene occurs in the normal brain. However, elevated
levels were also observed in other tissues like muscle, breast,
kidney, and prostate (Figure 1B). Remarkably, tumors in
those tissues lie among the group of cancers with higher
Tau/MAPT expression (Figure 1C), suggesting that this gene
could have other functions beyond chemoresistance and could
TABLE 1 | Correlation of the expression of different neurodegeneration-related genes with the clinical evolution of gliomas.
Normal brain/Primary
tumor/Recurrent









Media OS (days) high
expression





APP 7.92 N>P>R 2.3 G2>G3>G4 2660 1209 6 4
MAPT 9.88 N>P>R 241.1 G2>G3>G4 2975 489 148.8
APOE 6.57 N>P>R 42.2 G2>G3>G4 2660 918 44.2
Parkinson
PARK2 16.27 N>P>R 82.2 G2>G3>G4 2703 880 66.6
PINK1 13.23 N>P>R 77.1 G2>G3>G4 2660 919 45.2
SNCA 15.25 N>P>R 15.1 G2>G3>G4 2235 1137 13.1
UCHL1 10.48 N>P>R 13.9 G2>G3<G4 1233 2000 8.2
ALS
UBQLN2 7.95 N>P>R 104.4 G2>G3>G4 2875 737 106.5
HNRNPA2B1 4.88 N<P<R 4.4 G2>G3>G4 1120 2000 5.1
Analysis of the expression of genes related to AD, PD, and ALS on the TCGA merged dataset for LGG + GB (Normal brain/Primary tumor/Recurrent tumor, n = 701;
G2/G3/G4, n = 702; Overall survival (OS), n = 690 for the merged TCGA dataset (LGG + GB).
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be associated with intrinsic properties of the cells in the
different organs.
To gain further insight into the relevance of Tau in cancer we
analyzed the TCGA cohorts for different cancers and we used the
median of Tau/MAPT expression to classify tumors into High or
Low-Tau. We then studied if there were differences in the overall
survival of these two groups. In accordance with our previous
data (Table 1), gliomas with high levels of Tau/MAPT have a
much better prognosis (Table 2). However, the expression of
this gene also correlates with an increase in the overall survival
of patients with breast cancer, kidney clear cell carcinoma,
lung adenocarcinoma and pheochromocytoma/paraganglioma
(Table 2). By contrast, we found an inverse correlation between
the expression of Tau/MAPT and the survival of colon and head
and neck cancer (Table 2). However, those tumor have one of the
lowest transcriptional levels of this gene (Figure 2). By contrast,
it seems that Tau/MAPT mRNA is enriched in those cancers
in which it has a significant prognostic value, particularly for
breast and kidney tumors (Table 2). Collectively, these results
suggest that Tau could have an important role in gliomas, but
also in other cancers, beyond its competition with microtubule
stabilizing agents.
Tau/MAPT Is Expressed on Glioma Cells
and Correlates With a Less Aggressive
Behavior of These Tumors
The data presented here suggest that Tau/MAPT is expressed
in certain types of cancers, especially in the brain. Moreover, it
allow us to hypothesize that, in some cases, the expression of
this gene could be a marker of the less undifferentiated tumors
(those that show a better clinical behavior) that get lost during
the progression of the disease. In order to gain insight into the
possible role of Tau in cancer, particularly in gliomas, we analyzed
its expression in a panel of patient-derived-xenografts (PDXs).
In these subcutaneous xenografts, in the absence of Tau/MAPT
positive neurons, we observed that there is a variability in the
transcriptional levels of this gene (Figure 2A). We then chose
3 of these PDX, with high, intermediate and low expression
of Tau/MAPT, and we injected the dissociated cells into the
TABLE 2 | Prognostic value of Tau/MAPT in different cancers.
N Tau(MAPT)
exp (Median)








Acute myeloid leukemia 132 4.52 n.s
Adrenocortical cancer 79 6.91 n.s
Bile duct cancer 55 5.65 n.s
Bladder cancer 429 4.91 n.s
Breast cancer 1200 10.72 Yes 3736 3472 <0.0001 21.32
Cervical cancer 296 4.46 n.s
Colon cancer 315 6.83 No 1881 3041 0.0089 6.83
Endometrioid cancer 188 4.61 n.s
Esophageal cancer 196 4.74 n.s
Glioma 690 13.27 Yes 2875 489 <0.0001 148.8
Head and neck cancer 562 5.17 No 1090 1732 0.0073 7.19
Kidney clear cell carcinoma 604 10.47 Yes Undefined 2090 <0.0001 29.67
Large B-lymphoma 47 3.25 n.s
Liver cancer 417 6.63 n.s
Lung adenocarcinoma 564 5.31 Yes 1632 1423 0.0334 4.52
Lung cancer 1109 5.14 n.s
Melanoma 462 6.57 n.s
Mesothelioma 85 7.48 n.s
Ovarian cancer 307 5.16 n.s
Pancreatic cancer 182 6.15 n.s
Pheochromocytoma/Paraganglioma 185 12.13 Yes Undefined Undefined 0.0383 4.29
Prostate cancer 549 9.55 n.s
Rectal cancer 103 3.99 n.s
Sarcoma 265 6.15 n.s
Stomach cancer 421 4.92 n.s
Testicular cancer 139 5.21 n.s
Thymoma 121 7.23 n.s
Thyroid cancer 571 4.91 n.s
Uterine carcinosarcoma 56 6.24 n.s
Analysis of Tau/MAPT gene expression on the TCGA dataset for the different types of tumors. The median of Tau/MAPT expression was used to separate the high- and
low-Tau groups and to calculate the overall survival (OS). Log-rank (Mantel-Cox) analysis was performed to determine the Pro-Survival value of Tau/MAPT expression.
Bold words show relevant values for Tau/MAPT. N, number of patients enrolled. n.s., non-significant.
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FIGURE 2 | Tau/MAPT expression correlates with less aggressive glioblastomas of PDXs. (A) Quantification of Tau/MAPT mRNA expression levels by qPCR in 7
different glioblastomas derived from patients implanted in flanks of nude mice. Normal human brain tissue was used as control. (B) Kaplan meier curve of 3 PDXs
with different Tau expression levels implanted in the brain of nude mice (n = 6 for each group). (C) Tau expression levels analysis by western blot of tissue extracts of
the experiment described in B using GAPDH as loading control. (D) Quantification of Ki67 cells percentage by immunohistochemistry (IHC) of PDXs tissue of
samples described in (B). (E) Tau and GFAP expression analysis by IHC in tumor tissue of samples described in (B), showing Tau expression in green and GFAP in
red, of the PDXs with high and low expression of Tau. ∗∗∗p value < 0.0001, ∗∗p value < 0.01. Scale bar 25 µm.
brain of immunodeficient mice. We observed a striking inverse
correlation between the amount of Tau and the tumor growth
(Figures 2B,C). In fact, the more aggressive tumors show higher
proliferative index (Ki67 staining) (Figure 2D). Interestingly, the
analysis of the dissected GBM xenografts confirmed that Tau is
expressed in a high percentage of tumor cells (co-stained with a
GFAP antibody) in the Tau-high PDX, whereas there is very little
expression in the Tau-low PDX (Figure 2E). Altogether, these
results confirm the specific expression of Tau in glioma cells.
Moreover, they suggest that the levels of this protein correlate
inversely with the progression of this pathology.
DISCUSSION
Epidemiological evidences point toward an inverse comorbidity
of neurodegenerative diseases and cancer. This phenomenon
could be influenced by environmental factors and drug
treatments. However, genetic and molecular pathways should
have an important contribution as well. In fact, the two
maladies are characterized by opposing cellular behavior in
relation to cell growth and survival. In the case of AD, for
example, a pathogenesis model has been proposed based on
the up-regulation of tumor suppressors (Blalock et al., 2004).
In that sense, p53, which promotes apoptosis and protects
against cancer, is overexpressed in the central nervous system
(CNS) of patients diagnosed with a neurodegenerative disease
(Behrens et al., 2009). Others have found that several genes and
pathways are upregulated in CNS disorders but downregulated
in cancer and the other way round (Ibanez et al., 2014).
This particular study has confirmed the dual role for the p53
pathway as well as for two other candidates, the enzyme Pin1
and the Wnt pathway, which are overexpressed or activated in
most cancers but downregulated in AD (Behrens et al., 2009).
More recently, another functional analysis has suggested that
proteosomal, protein folding and mitochondrial processes are
regulated oppositely in AD and lung cancer (Sanchez-Valle et al.,
2017). The same study found a significant number of immune
system and oxidative-phosphorylation-related genes that were
deregulated in the same direction in AD and aggressive gliomas.
More recently, it has been proposed that GBM-secreted CD44
could induce neuronal degeneration through the activation
of Tau pathologies in the brain (Lim et al., 2018). These
findings suggest a positive correlation between the last two
diseases, something that had already been proposed (Lehrer,
2010, 2018). However, there are no robust epidemiological data
on the incidence of gliomas in AD patients or vice versa,
probably due to the low frequency of these tumors. Moreover,
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there are also discrepancies at the molecular level as other
authors have found that the ERK/MAPK (associated with cell
proliferation and survival) and the Angiopoietin (associated to
angiogenesis) signaling pathways are oppositely regulated in
the two diseases (Liu et al., 2013). Given this controversy we
decided to perform a comprehensive characterization in gliomas
of the genetic and transcriptomic status of genes associated with
neurodegenerative diseases.
Despite the lack of genetic alterations of our panel of
neurodegenerative genes in gliomas, we have observed an
important correlation of their transcriptional expression with the
clinical behavior of this type of cancer. It is true that almost
all the genes tested have a higher expression in normal tissue
compared to primary gliomas, nevertheless this could reflect
that they are enriched in neurons in comparison to glial cells.
However, the most relevant data is that their transcriptional levels
diminish in parallel with the clinical evolution of the disease: after
recurrence and during the progression of gliomas from low to
higher grade tumors. Among the studied genes, we decided to
focus onTau/MAPT, as it shows the strongest correlation with the
clinical evolution of gliomas. We performed an in vivo analysis,
with ortho and hetherotopic glioma xenografts, which confirmed
that Tau protein is truly expressed in the astrocytic tumor
cells. Moreover, we validated the inverse correlation between the
Tau and glioma growth. Therefore, our findings suggest that
Tau/MAPT, and some other genes whose alterations are linked
to neurodegenerative diseases, are enriched in the less aggressive
gliomas and they probably need to be downregulated for these
tumors to progress. This phenomenon could explain their
positive correlation with survival in almost all the cases analyzed.
It is worth mentioning that there have been previous reports
of deregulations (mutations and copy number losses) observed
in PARK2 in GBM (Veeriah et al., 2010), which argue in favor
of a possible tumor suppressor function of this gene in such
tumors. Still, our meta-analysis indicates a lower frequency of
PARK2 deletions in the joint cohort of gliomas. However, we only
accounted for those CNV that appear in homozygosity, which
could explain why we found a reduced percentage of gliomas with
these deletions. Nevertheless, our transcriptomic data further
supports that this protein could be inhibiting glioma growth as it
has been suggested by others (Yeo et al., 2012; Viotti et al., 2014;
Gupta et al., 2017). Regarding Tau, it has been recently reported
that families affected by genetic tauopathies have a higher risk
of developing cancer (Rossi et al., 2018). However, our analysis
has found a very small percentage of gliomas (0.3%) with Tau
alterations (amplifications and deletions).
Although Tau is highy expressed in neuronal axons, there
were evidences of its presence in glial cells (LoPresti et al.,
1995) and even in gliomas (Lopes et al., 1992; Miyazono
et al., 1993). Moreover, the levels of Tau had been recently
associated with LGG survival rates (Zaman et al., 2019),
although its role in brain cancer was largely unknown. Our
results suggest that gliomas need to lose Tau expression in
order to progress into a more aggressive entity. In AD and
other tauopathies, it has been postulated that changes in
the expression of the different Tau/MAPT splicing isoforms
might facilitate the neurodegeneration. Besides, Tau becomes
increasingly phosphorylated in AD, which is the first step in
the formation of toxic aggregates of the protein (gain of toxic
function). The phosphorylation and subsequent aggregation of
Tau compromises its microtubule-stabilizing functions (loss of
physiological function), favoring the evolution of the pathology.
In agreement with the loss-of-function model, several groups
have reported behavioral changes and neurogenesis in aged Tau
knockout mice (Pallas-Bazarra et al., 2016). Therefore, we could
postulate that Tau expression and/or function might be lost
during the progression of both, gliomas and AD, which might
contribute to explain the correlation between the two diseases
observed by certain authors. Nevertheless, the mechanism for
Tau inhibition could be seemingly different: gene expression
regulation in gliomas and posttraductional modifications in AD
and other Tauopathies.
In relation to Tau function, our results suggest that the
stabilization of the microtubule network might be needed in the
earliest stages of gliomas, but it would be lost as the tumors
progress. Tau overexpression in immortalized cell lines induces
a plethora of changes in the location and trafficking of different
organelles, including mitochondria and endosomes. This leads
to a decrease in cell proliferation (Ebneth et al., 1998), which
could be associated with the reduction in tumor growth that
we have observed in the Tau-high gliomas. Moreover, changes
in the dynamics of the microtubular cytoskeleton might have
important implications in the motility of the tumor cells, affecting
their invasive capacity. In adition, the microtubules participate
in the process of epithelial-to-mesenchymal transition (EMT),
which also occur in gliomas and has been associated with
an increase in the aggressivity of these tumors (Bhat et al.,
2013). In fact, the higher expression of Tau/MAPT in lower
degree gliomas suggest that it could be an accumulation of this
protein in the so-called Proneural tumors, which have a better
prognosis and tend to suffer a process of mesenchymalization
after tumor recurrence (Bhat et al., 2013). Interestingly, we
have shown that Proneural gliomas are more prone to invasion
whereas mesenchymal tumors are more angiogenic (Garcia-
Romero et al., 2016). Therefore, we could speculate that changes
in Tau expression could affect at the same time the EMT and
the invasion capacity of the glioma cells. In fact, a recent article
suggests that Tau downregulation in a glioma cell line leads
to a decrease in cell motility (Breuzard et al., 2019). Future
experiments will help to determine if Tau is an active or passive
actor on these phenotypes.
Appart for the control of the microtubule dynamics, Tau
has been implicated in other functions like maintenance of
the RNA/DNA integrity and the nuclear structure. In addition,
Tau contains several domains with a broad pattern of binding
partners, including other cytoskeletal molecules that could
participate in the regulation of protein transport (Medina et al.,
2016; Wang and Mandelkow, 2016). Besides, Tau interacts with
a plethora of kinases, phosphatases, chaperones and membrane
proteins (Mandelkow and Mandelkow, 2012) and many of those
could be Tau partners in cancer. Indeed, it has been shown that
in prostate cancer cells, Tau binds to PI3K (phosphatidylinositol
3-kinase) (Souter and Lee, 2009). Furthermore, it has been shown
to activate MAPK (Mitogen-activated protein kinase) in response
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to NGF (nerve growth factor) and EGF (epidermal growth
factor) (Leugers and Lee, 2010). Both, PI3K and MAPK are
important regulators of glioma growth and survival (Ceccarelli
et al., 2016). More recently, Tau deletion has been linked to
defects in the insulin signaling pathway in the brain (Marciniak
et al., 2017). This could explain why patients with AD appear
to be insulin resistant (Talbot et al., 2012). Moreover, it could
be the cause of the repression of the orthotopic growth and
vascularization of gliomas in genetic mouse models of AD
(Paris et al., 2010). Alternatively, we could hypothesize that
the decrease in Tau function could participate in the brain
neuroinflammation observed in AD models and that this
phenomena could favor glioma growth (Sanchez-Valle et al.,
2017; Laurent et al., 2018). Indeed, higher levels of inflammatory
markers have been observed in the brains of AD mice, which are
more prone to develop tumors in the presence of carcinogens
(Serrano et al., 2010). Future experiments will help to solve
these apparent discrepancies in the frequency of cancer in
AD mouse models.
Another important corollary of our study is the possibility
that microtubules-stabilizing compounds could imitate Tau
and hinder glioma growth. Among these molecules the most
commonly used are the taxanes, including paclitaxel and
docetaxel, which serve as chemotherapy agents in different
cancers. Although they can reduce glioma growth in vitro, the
clinical trials were not successful due to limitations in their
ability to cross the blood brain barrier (Glantz et al., 1999).
However, there have been promising results with the next-
generation of taxanes like epothilone D and cabazitaxel, which
can penetrate the brain and have good anti-tumor activity
in mouse glioma models (Semiond et al., 2013). Cabazitaxel
has been evaluated with a limited success in a phase II
study for temozolomide refractory gliomas (NCT01740570 and
NCT01866449) and now is being investigated clinically in
combination with cisplatin.
High tau mRNA expression has been associated with
a more favorable prognosis in breast cancer (Shao et al.,
2010; Baquero et al., 2011). These results were confirmed
in the present study (Table 2). Moreover, we have extended
these results to other unreported cancers, like Kidney Clear
Cell Carcinoma. Interestingly, it has been proven that Tau
expression has a predictive value for estrogen receptor
(ER)-positive breast cancer. In those tumors high levels
of Tau are considered a surrogate marker for endocrine-
sensitive but otherwise chemotherapy-resistant samples
(Pentheroudakis et al., 2009; Shao et al., 2010; Bonneau
et al., 2015). By contrast, low Tau expression identifies a
subset of ER-positive breast cancers that have poor prognosis
when treated with tamoxifen alone, although they may
benefit from chemotherapy with taxanes (Rouzier et al.,
2005; Andre et al., 2007; Pentheroudakis et al., 2009; Tanaka
et al., 2009; Shao et al., 2010; Bonneau et al., 2015). Similarly,
Tau-negative expression has been related to a favorable
response to Paclitaxel treatment in gastric (Mimori et al.,
2006; Wang et al., 2013; He et al., 2014; Yu et al., 2014) and
bladder cancer (Wosnitzer et al., 2011). Translating these
results into gliomas, our findings suggest that Tau-positive
expression could identify a subset of tumors with slowest
progression (including those with a higher sensitivity to the
standard chemo-radiation therapy). By contrast, low-Tau
expression could be a marker of a subset of gliomas that has
a poorer prognosis. However, those tumors might benefit
from chemotherapies with taxane-derivatives, like cabazitaxel.
Therefore, it will be interesting to quantify the value of
Tau expression as a surrogate marker in the clinical trials
with this compound.
Increasing efforts have focused on the physiological vs.
the pathological properties of Tau, investigating mechanisms
of neuronal dysfunction attributed to loss-of-normal or gain-
of-toxic Tau function in AD and other neurodegenerative
pathologies. However, despite the evidences that support a novel
role for Tau in cancer, we know very little about the mechanisms
that control the expression and/or the function of this protein in
tumor cells or in their microenvironment. The results presented
here underlines the relevance of Tau in cancer, beyond its capacity
to compete with chemotherapy compounds. We propose that this
protein might serve as a brake in the evolution of the pathology
of several tumors, especially in gliomas and certain breast and
kidney cancers, where it is highly expressed. We believe that a
profound characterization of the expression and function of Tau
in normal and tumorigenic glial cells is needed. These studies
will probably uncover novel aspects of the biology of this protein
that could help to unravel the etiology of several cancers and
neurodegenerative diseases.
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